Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Evogene ( (EVGN) ) is now available.
On May 20, 2026, Evogene reported first-quarter 2026 results, highlighting the post-2025 strategic focus on its ChemPass AI engine and pipeline in pharma and agriculture, alongside the wind-down of non-core subsidiaries. Management is concentrating resources on AI-driven small-molecule discovery, expanding collaborations and tightening its portfolio, moves that are reshaping the company’s risk profile and future revenue mix.
Operationally, Evogene signed three new pharma collaborations, advanced AgPlenus herbicide and fungicide programs, but saw a Bayer herbicide project terminated, with associated assets reverting to its AgPlenus unit. Financially, Q1 revenue dropped to about $0.3 million from $2.3 million a year earlier due mainly to lower Casterra seed sales, operating loss widened slightly to $3.2 million, and net financing expenses surged due to warrant accounting, even as cash stood at $13.1 million, supplemented by a February warrant-induced capital raise and expected dividends from Lavie Bio and Biomica.
The company is also unwinding or refocusing non-core units: Lavie Bio ceased operations with planned shareholder dividends, Biomica licensed its lead oncology candidate and is distributing cash to shareholders, and Casterra is narrowing efforts to Brazil ahead of planned 2027 seed sales. These actions, along with structured warrant financing and cost controls in R&D and G&A, signal a transition toward a more focused, capital-disciplined platform player in AI-driven pharma and ag-chem innovation.
The most recent analyst rating on (EVGN) stock is a Buy with a $2.25 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, heavy cash burn, negative equity, and declining revenue). Technicals also reflect a downtrend with negative momentum. The earnings call provides partial support through sustained cost cuts and near-term liquidity actions, but top-line weakness and one-time items keep overall risk elevated.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd., listed on Nasdaq and TASE, is a computational chemistry company specializing in generative AI design of small molecules for the pharmaceutical and agricultural industries. The company’s ChemPass AI platform underpins its pharma collaborations and ag-chemical programs, while non-core subsidiaries such as Lavie Bio, Biomica and Casterra are being wound down or refocused under a strategy shift begun in 2025.
Evogene’s business model blends internal drug and crop-protection R&D with partnerships, including work with Corteva on herbicides and academic and biotech partners on inflammatory and oncology indications. The firm is also deepening technology collaborations, such as its integration of advanced AI tools via Google Cloud, to enhance multi-parameter optimization and discovery of novel, high-potency small molecules.
Average Trading Volume: 100,555
Technical Sentiment Signal: Sell
Current Market Cap: $8.47M
For an in-depth examination of EVGN stock, go to TipRanks’ Overview page.